Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.820
-0.020 (-0.41%)
Apr 28, 2026, 4:08 PM HKT
9.79%
Market Cap 16.47B
Revenue (ttm) 6.10B
Net Income (ttm) 388.91M
Shares Out n/a
EPS (ttm) 0.27
PE Ratio 42.34
Forward PE n/a
Dividend 0.27 (5.54%)
Ex-Dividend Date May 26, 2025
Volume 150,500
Average Volume 377,925
Open 4.830
Previous Close 4.840
Day's Range 4.810 - 4.850
52-Week Range 4.320 - 7.260
Beta 0.45
RSI 34.69
Earnings Date Mar 30, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Sector Healthcare
Founded 1998
Employees 2,150
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9989
Full Company Profile

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY

News

There is no news available yet.